SCHEMBL26700563

SCHEMBL26700563

CC(C)CNC(=O)CCOCCOCCNC(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HPGD P15428 3/20 0.41
KDM4E B2RXH2 4/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
RECQL P46063 1/20 0.36
EPHX2 P34913 4/20 0.35
CA12 O43570 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.33
MMP1 P03956 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25602351 0.86 HPGD (0.50) MEN1KMT2AHPGDCYP2D6CYP2C19
SCHEMBL26034210 0.85 HPGD (0.34) MEN1KMT2AHPGDKDM4EPOLB
SCHEMBL20466152 0.84 MEN1 (0.44) MEN1KMT2AHPGDKDM4EPOLB
SCHEMBL20466149 0.84 MEN1 (0.44) MEN1KMT2AHPGDKDM4EPOLB
SCHEMBL22856965 0.84 MEN1 (0.46) MEN1KMT2AHPGDKDM4ECYP2D6
SCHEMBL29299575 0.83 HPGD (0.41) MEN1KMT2AHPGDKDM4EPOLB
SCHEMBL23879753 0.83 MEN1 (0.45) MEN1KMT2AHPGDCYP2D6CYP2C19
SCHEMBL21575545 0.83 KMT2A (0.53) MEN1KMT2AHPGDCYP2D6CYP2C19
SCHEMBL21786693 0.83 MEN1 (0.45) MEN1KMT2AHPGDPOLBCYP2D6
SCHEMBL24621958 0.83 KMT2A (0.45) MEN1KMT2AHPGDKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348452-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 MEN1 1155/4885KMT2A 927/4885HPGD 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.